Published in Vaccine on May 14, 2001
Influenza vaccines: present and future. J Clin Invest (2002) 1.74
A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates. J Virol (2007) 1.50
Identifying influenza viruses with resequencing microarrays. Emerg Infect Dis (2006) 1.45
Influenza vaccines. Vaccine (2009) 1.17
What drives chytrid infections in newt populations? Associations with substrate, temperature, and shade. Ecohealth (2010) 1.09
Comparative study of influenza virus replication in MDCK cells and in primary cells derived from adenoids and airway epithelium. J Virol (2012) 0.99
RNA replicons - a new approach for influenza virus immunoprophylaxis. Viruses (2010) 0.97
Engineering temperature sensitive live attenuated influenza vaccines from emerging viruses. Vaccine (2012) 0.96
Virus aggregating peptide enhances the cell-mediated response to influenza virus vaccine. Vaccine (2011) 0.85
Generation of influenza A viruses with chimeric (type A/B) hemagglutinins. J Virol (2003) 0.85
Computational codon optimization of synthetic gene for protein expression. BMC Syst Biol (2012) 0.85
Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine (2012) 0.85
All-in-one bacmids: an efficient reverse genetics strategy for influenza A virus vaccines. J Virol (2014) 0.81
Reverse genetic platform for inactivated and live-attenuated influenza vaccine. Exp Mol Med (2010) 0.81
Technology Resource, Distribution, and Development Characteristics of Global Influenza Virus Vaccine: A Patent Bibliometric Analysis. PLoS One (2015) 0.81
Bursopentine as a novel immunoadjuvant enhances both humoral and cell-mediated immune responses to inactivated H9N2 Avian Influenza virus in chickens. Clin Vaccine Immunol (2011) 0.80
Improved hatchability and efficient protection after in ovo vaccination with live-attenuated H7N2 and H9N2 avian influenza viruses. Virol J (2011) 0.76
Microneedle Vaccination Elicits Superior Protection and Antibody Response over Intranasal Vaccination against Swine-Origin Influenza A (H1N1) in Mice. PLoS One (2015) 0.75
Development of a stable liquid formulation of live attenuated influenza vaccine. Vaccine (2016) 0.75
A murine model for assessment of living attenuated influenza A vaccines. Aust J Exp Biol Med Sci (1980) 1.62
Relative immunogenicity of the cold-adapted influenza virus A/Ann Arbor/6/60 (A/AA/6/60-ca), recombinants of A/AA/6/60-ca, and parental strains with similar surface antigens. Infect Immun (1984) 1.52
Biophysical and biochemical characterization of hepatitis A virus. Intervirology (1982) 1.49
A re-examination of the molecular weight of poliovirus RNA. Biochem Biophys Res Commun (1970) 1.18
Quantitation of antibody to non-hemagglutinating viruses by single radial hemolysis: serological test for human coronaviruses. J Clin Microbiol (1977) 1.17
Evidence that the genome of hepatitis A virus consists of single-stranded RNA. J Virol (1981) 1.14
Humoral and cellular responses of mice to infection with a cold-adapted influenza A virus variant. Infect Immun (1982) 1.05
Further characterization of the genetic map of poliovirus temperature-sensitive mutants. In: strategy of the viral genome. Ciba Found Symp (1971) 1.00
The RNA of human coronavirus OC-43. Virology (1977) 0.92
The sensitization of mice with a wild-type and cold-adapted variant of influenza A virus. II. Secondary cytotoxic T cell responses. Immunology (1984) 0.90
The nucleic acid of infectious bronchitis virus. Arch Gesamte Virusforsch (1973) 0.88
Preparation and characterisation of attenuated cold-adapted influenza A reassortants derived from the A/Leningrad/134/17/57 donor strain. Vaccine (2002) 0.88
Homotypic and heterotypic immunity of influenza A viruses induced by recombinants of the cold-adapted master strain A/Ann Arbor/6/60-ca. Arch Virol (1987) 0.88
Presence of genomic polyadenylate and absence of detectable virion transcriptase in human coronavirus OC-43. J Gen Virol (1978) 0.87
The role of cell culture vaccines in the control of the next influenza pandemic. Expert Opin Biol Ther (2004) 0.87
A clearance test in mice using non-adapted viruses to determine the immunogenicity of influenza strains. Arch Virol (1981) 0.84
Immunogenic and isotype-specific responses to Russian and US cold-adapted influenza a vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/Ann Arbor/6/60 (H2N2) in mice. J Med Virol (2001) 0.83
Nucleic acid of infectious laryngotracheitis virus. Nature (1965) 0.82
Immunization against influenza by the ocular route. Vaccine (1985) 0.82
Evaluation of chicken kidney and chicken embryo kidney cultures for the large-scale growth of attenuated influenza virus master strain A/Ann/Arbor/6/60-ca. Vaccine (1985) 0.82
Responses to one or two doses of a deoxycholate subunit influenza vaccine in a primed population. Vaccine (1984) 0.81
Respiratory syncytial virus: a review of the virus, its epidemiology, immune response and laboratory diagnosis. Aust Paediatr J (1986) 0.80
The role of reverse genetics in the development of vaccines against respiratory viruses. Expert Opin Biol Ther (2005) 0.80
Subgrouping of respiratory syncytial virus strains from Australia and Papua New Guinea by biological and antigenic characteristics. Arch Virol (1994) 0.80
Interference between cold-adapted (ca) influenza A and B vaccine reassortants or between ca reassortants and wild-type strains in eggs and mice. Vaccine (1994) 0.79
A model for determining immunogenic relationships between avian infectious bronchitis viruses. Arch Virol (1990) 0.79
Western blot analysis of antibody responses to influenza virion proteins. Immunol Cell Biol (1992) 0.78
A simple procedure for the analysis of the structural proteins of influenza and parainfluenza viruses involving adsorption to erythrocytes. J Virol Methods (1984) 0.78
Field evaluations of safety and efficacy of an Australian Marek's disease vaccine. Aust Vet J (2003) 0.78
The growth of attenuated influenza vaccine donor strains in continuous cell lines. J Virol Methods (2005) 0.77
Some characteristics of a recent virulent isolate of Marek's disease virus. Aust Vet J (1994) 0.77
Protective responses in mice to vaccination with multiply administered cold-adapted influenza vaccine reassortants and wild-type viruses. Vaccine (1997) 0.76
An evaluation of the genetic stability and pathogenicity of the Russian cold-adapted influenza A donor strains A/Leningrad/134/17/57 and A/Leningrad/134/47/57 in ferrets. J Virol Methods (2003) 0.76
Efficacy of Australian vaccines against recent isolates of avian infectious bronchitis viruses. Aust Vet J (1991) 0.76
A device for the nondestructive decontamination of large volumes of infected egg waste. Appl Environ Microbiol (1985) 0.75
Membrane filtration enzyme immunoassay, a novel, rapid method for measurement of virus-specific immunoglobulins G and M and detection of viral antigens. J Clin Microbiol (1987) 0.75
Development and application of an improved infectivity assay for the standardization of avian encephalomyelitis vaccines. Vaccine (1990) 0.75
Development and application of an ELISA technique for the detection of antibody to avian encephalomyelitis viruses. Res Vet Sci (1989) 0.75
Adaptation of Marek's disease virus to the Vero continuous cell line. Vet Microbiol (2001) 0.75
The development and evaluation of two tissue culture-grown Marek's disease challenge viruses. Avian Pathol (1998) 0.75
An enzyme-linked immunosorbent assay for the detection of avian encephalomyelitis virus antigens. Avian Dis (1988) 0.75
A study of the advantages and limitations of immunoblotting procedures for the detection of antibodies against influenza virus. Electrophoresis (1993) 0.75
An improved membrane-filtration enzyme immunoassay for the rapid serological diagnosis of viral infections. J Virol Methods (1988) 0.75
Age-related responses to influenza vaccination in the Newcastle region during 1983 and 1984. Med J Aust (1987) 0.75
Options for the control of influenza III. Cairns, North Queensland, Australia (4-9 May 1996). Vaccine (1997) 0.75
Degradation of myxovirus virion RNA by periodate. Intervirology (1975) 0.75
Prospects of a living attenuated vaccine against influenza. Aust J Exp Biol Med Sci (1980) 0.75
Isolation of serotype 1 Marek's disease viruses from vaccinated Australian flocks. Vet Microbiol (1995) 0.75
The development of an improved experimental yellow fever vaccine. J Biol Stand (1980) 0.75
Diagnosis of a field outbreak of avian encephalomyelitis by enzyme-linked immunosorbent assay. Aust Vet J (1989) 0.75
Further evidence that the nucleic acid of avian encephalomyelitis virus consists of RNA. Avian Dis (1993) 0.75
The antigenicity of the chicken anaemia virus protein VP3 (Apoptin). Avian Pathol (2001) 0.75
Antibody responses to avian encephalomyelitis virus vaccines when administered by different routes. Aust Vet J (1992) 0.75
A comparative evaluation of chicken embryo tracheal organ cultures for the assay of avian infectious bronchitis virus. J Biol Stand (1978) 0.75
The development and evaluation of a cell culture vaccine against infectious laryngotracheitis virus. J Biol Stand (1979) 0.75
The RNA and proteins of human coronaviruses. Adv Exp Med Biol (1981) 0.75
Derivation, safety and efficacy of a Marek's disease vaccine developed from an Australian isolate of very virulent Marek's disease virus. Aust Vet J (2002) 0.75
Immunization against influenza by the ocular route. Brief report. Arch Virol (1983) 0.75
Pathogenesis of avian encephalomyelitis viruses. J Gen Virol (1991) 0.75
Purification of adenovirus 4 type-specific hemagglutinins for use in diagnostic counterelectrophoresis tests. J Med Virol (1979) 0.75
Attempts to extend the genetic map of poliovirus temperature-sensitive mutants. J Gen Virol (1975) 0.75
Interferon-new wonder drug or old laboratory curiosity? Med J Aust (1981) 0.75
A rapid procedure for the purification of avian encephalomyelitis viruses. Avian Dis (1985) 0.75